Researchers are analyzing gene expression signatures to better predict which therapy will work best for each patient with cancer.
Uproleselan May Improve Remission, Reduce Side Effects in Patients with Acute Myeloid Leukemia
The addition of uproleselan to standard chemotherapy regimens may reduce the rate of remission, low-induction mortality and mucositis in patients with relapsed or refractory acute myeloid leukemia.
Biomarkers Predict Outcomes of CAR T-Cell Therapy in Patients with Diffuse Large B-Cell Lymphoma
New research shows that CAR T-cell therapy may be a more effective option for patients with relapsed or refractory diffuse large B-cell lymphoma than traditional first-line chemoimmunotherapy.
Noninvasive Assessment of Sarcopenia May Predict Tolerance to Neo(adjuvant) Chemotherapy in Early-Stage Breast Cancer
A new study of patients with early breast cancer suggests that the noninvasive assessment of sarcopenia using bioelectrical impedance analysis can help predict toxicity from adjuvant or neoadjuvant chemotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Adding Daratumumab to Treatment Regimen May Improve Outcomes in Patients With Immunoglobulin Light-Chain Amyloidosis
The anticancer drug daratumumab appears to offer significant benefits – including a promising safety profile – when used as part of a three-drug regimen to treat patients with immunoglobulin light-chain amyloidosis, a protein disorder that most commonly affects the heart and kidneys.
Study Supports Single-Dose Rasburicase for Tumor Lysis Syndrome
Findings from a Cleveland Clinic-led study suggest that a single, weight-based dose of rasburicase is effective in preventing tumor lysis syndrome in children, adolescents and young adults.
AMH Peptide Mimic May Hold Key to Fertility Preservation in Chemotherapy Patients
Many women receiving chemotherapy face the prospect of premature menopause because the drugs destroy ovarian follicles. New research is helping to unlock the keys to use of AMHR2BP, a peptide that mimics anti-Müllerian hormone, to preserve fertility in these patients.
Chemo Plus Immunotherapy Shows Promise for Advanced Bladder Cancer
The combination of nivolumab, gemcitabine and cisplatin produces significant pathologic response rates in patients with muscle-invasive bladder cancer (MIBC) in the neoadjuvant setting, according to new data from the phase II Bladder Cancer Signal Seeking Trial.
Study Reinforces Concerns about Dietary Supplement Use and Breast Cancer Treatment
Breast cancer patients’ use of certain dietary supplements before and during chemotherapy is linked to an increased risk of disease recurrence and death, a recent study involving Cleveland Clinic researchers has found.
Radiation Heart Disease: A Few Learnings on a Diverse, Daunting Entity
When cancer radiation therapy does collateral damage to the heart, patients pose latent clinical challenges that demand a true center of excellence.